HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $113.
June 26, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $113.
The reiteration of a Buy rating and maintenance of a $113 price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for BioNTech.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100